ReviewOptimizing outcome in SLE: treating-to-target and definition of treatment goals
Introduction
Survival of patients with systemic lupus erythematosus (SLE) has dramatically improved over the last 50 years, increasing from 50% at 10 years in the fifties to more than 90% in 2000s [1], possibly owing to earlier diagnosis and more appropriate treatment schemes [2]. However, SLE patients still display a 4.6-fold higher standardized mortality rate compared with general population [3]. Causes of death have been varying deeply along with the increase in survival rates, with less patients dying due to acute disease and a greater percentage succumbing to cardiovascular events, infections or cancer [2], [4], [5]. Notably, persistent disease activity is associated with increased organ damage which in turn is predictive of more damage and death [6], [7], [8] (Fig. 1). Hence, several needs are still unmet among SLE population in that long-term prognosis remains poor; therefore, new methodological strategies should be found out aiming to prolong remission and minimize damage accrual. The aim of our paper is to shed more light on optimizing strategies in SLE focusing on treat-to-target, importance of early treatment and judicious corticosteroid use, which might reduce damage accrual and improve disease outcome.
Section snippets
Treat-to-target
Treat-to-target may be defined as a therapeutic strategy aimed to treat patients to a goal which is capable of improving disease outcome. The basis according to which one may pinpoint the best target to be treated to is mostly provided by clinical trials [9], [10]. As an example, current guidelines for diabetes and cardiovascular disease management outline the treatment thresholds which confer the highest probability of survival to patients at risk of adverse events (e.g. a total LDL-cholesterol
SLE disease activity
Lupus activity can be defined as a variable which represents the sum of all abnormalities due to ongoing immune inflammatory pathways involved in SLE which are mostly reversible.
Lupus activity may be distinguished into clinical and serological disease activity (Table 1), which encompass inflammatory/non-inflammatory manifestations affecting any district in the body and persistent serological abnormalities, among which the presence of autoantibodies, especially anti-dsDNA antibodies, low C3
SLE and organ damage
Damage in SLE is defined as an irreversible tissue injury occurring after diagnosis of SLE and lasting at least 6 months [31]; it is evaluated through the SLICC (Systemic Lupus International Collaborating Clinics) damage index (SDI), which encompasses 12 organ systems [31]. Interestingly, disease activity tends to generally decline over time, along with a parallel worsening in diverse damage domains [32], [33], [34]. Therefore, since lupus patients live longer, they tend to accumulate more
Organ damage predicts poor outcome
Damage is one of the major determinants of poor long term prognosis and death in SLE patients. It can also lead to disability and productivity loss.
Remission is associated with a better outcome
Results from a large multicentric inception cohort of SLE patients prospectively followed for 5 years showed that disease remission and particularly early remission is predictive for a better outcome in SLE [15], whereas long term prognosis remains poor in active patients [15], [74]. As an example, it is worth noting that renal survival is increased in patients who achieve either complete or partial disease remission in comparison with severely-affected patients, whereas overall survival at 20
Remission in SLE
Remission in SLE is not clearly defined by any of the available disease activity scores [77]. According to SLEDAI, remission may be defined as a SLEDAI = 0, whereas SLEDAI ≥ 3 was referred to as persistent disease activity [78], [79], thus raising the question what significance be given to serologic abnormalities such as anti-double stranded (ds)DNA antibodies or complement levels.
SLE activity measures are not commonly used in routine follow-up visits, thus if we look at clinical practice, at least
Definition of treatment goals
Long-term complete remission is the primary target that SLE patients should be treated to, since durable remission is associated with a better outcome in terms of reduced disease flares and damage accrual. However, complete remission is often hard to accomplish for the majority of SLE patients, whereas clinical remission without corticosteroids or with a minimal dose of corticosteroids could be acceptable alternative targets. Though it is not included in the SLE wish-list, low disease activity
Early treatment and the window of opportunity in SLE
It is worth noting that clinical recommendations for lupus management all agree on the need of early initiation of adequate therapy [86], [87], [88], [89], regardless of which organ is affected and what drug is specifically proposed for treatment. As aforementioned, the sooner the treatment is started, the higher is the chance of achieving persistent remission and improve patients prognosis [74]. Data on early intervention in humans are currently limited, however existing studies clearly show
Conclusions
Achievement of a more favorable outcome in SLE is closely due to tight control of disease activity and prolonged remission. Patients should be treated to complete remission since it is associated with the best outcome; however, clinical remission or even low disease activity with low doses of steroids are acceptable alternative therapeutic targets. Early diagnosis is essential in order for patients to be efficiently treated (better if within 3–5 months from clinical disease onset) and enter an
Take-home messages
- •
Treat to target refers to treating patients to a definite value of disease, which significantly improves a patient's condition.
- •
Complete remission is the main treat-to-target in SLE, yet partial remission or low disease activity may be acceptable.
- •
Early treatment in SLE prevents organ damage and is predictive of durable remission.
- •
Tight balance between therapeutic harm and benefit has to be provided and prompt corticosteroids withdrawal is recommended.
- •
More reliable biomarkers and outcome measures
References (103)
- et al.
Global trend of survival and damage of systemic lupus erythematosus: meta-analysis and meta-regression of observational studies from the 1950s to 2000s
Semin Arthritis Rheum
(2012) - et al.
Long-term prognosis and causes of death in systemic lupus erythematosus
Am J Med
(2006) - et al.
Cardiovascular protection and blood pressure reduction: a meta-analysis
Lancet
(2001) - et al.
Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices
Best Pract Res Clin Rheumatol
(2005) - et al.
The Systemic Lupus Erythematosus Responder Index (SRI); a new SLE disease activity assessment
Autoimmun Rev
(2012) - et al.
The bimodal mortality pattern of systemic lupus erythematosus
Am J Med
(1976) - et al.
SLE diagnosis and treatment: when early is early
Autoimmun Rev
(2010) - et al.
Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide
Kidney Int
(2000) Review of classification criteria for systemic lupus erythematosus
Rheum Dis Clin North Am
(2005)- et al.
Emerging and critical issues in the pathogenesis of lupus
Autoimmun Rev
(2013)
Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort
Rheumatology
Premature coronary heart disease in SLE: can we prevent progression?
Lupus
Death causes and pathogens analysis of systemic lupus erythematosus during the past 26 years
Clin Rheumatol
Global trends, potential mechanisms and early detection of organ damage in SLE
Nat Rev Rheumatol
Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus
Lupus
High predictive value of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for survival in systemic lupus erythematosus
J Rheumatol
‘Treat to target’: moving targets from hypertension, hyperlipidaemia and diabetes to rheumatoid arthritis
Ann Rheum Dis
European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice
Eur Heart J
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary
Eur Heart
Evidence for treating rheumatoid arthritis to target: results of a systematic literature search
Ann Rheum Dis
Treating rheumatoid arthritis to target: recommendations of an international task force
Ann Rheum Dis
Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus
Lupus
Tools for monitoring remission in rheumatoid arthritis: any will do, let's just pick one and start measuring
Arthritis Res Ther
BILAG, SLEDAI, SIS, ECLAM, WAM, SLAM … thank you MAM
Lupus
Reliability and validity of six systems for the clinical assessment of disease activity in SLE
Arthritis Rheum
Derivation of the SLEDAI. A disease activity index of lupus patients
Arthritis Rheum
Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research
Clin Exp Rheumatol
The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus
Q J Med
The lupus activity criteria count (LACC)
J Rheumatol
Clinical and serological features
Patterns of disease activity in systemic lupus erythematosus
Arthritis Rheum
Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study
Clin Exp Rheumatol
Prolonged remission in systemic lupus erythematosus
J Rheumatol
SLE disease patterns in a Danish population-based lupus cohort: an 8-year prospective study
Lupus
Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome
J Rheumatol
The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus
Arthritis Rheum
Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years
Rheumatology (Oxford)
Current causes of death in systemic lupus erythematosus in Europe, 2000–2004: relation to disease activity and damage accrual
Lupus
Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus
J Rheumatol
Prednisone, lupus activity, and permanent organ damage
J Rheumatol
Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus — a 5-yr prospective study
Rheumatology
Accrual of organ damage over time in patients with systemic lupus erythematosus
J Rheumatol
Damage in systemic lupus erythematosus and its association with corticosteroids
Arthritis Rheum
Damage accrual in southern Chinese patients with systemic lupus erythematosus
J Rheumatol
Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort
Rheumatology (Oxford)
Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality
J Rheumatol
Disease course in systemic lupus erythematosus: changes in health status, disease activity, and organ damage after 2 years
J Rheumatol
Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage
Rheumatology
Systemic lupus erythematosus in a multiethnic US cohort(LUMINA): XXII. Predictors of time to the occurrence of initial damage
Arthritis Rheum
Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort
Arthritis Care Res
Cited by (103)
Clinical patterns of disease: From early systemic lupus erythematosus to late-onset disease
2024, Best Practice and Research: Clinical RheumatologyAssessment of disease activity and damage in SLE: Are we there yet?
2023, Best Practice and Research: Clinical RheumatologyCaveats and pitfalls in defining low disease activity in systemic lupus erythematosus
2022, Autoimmunity ReviewsCitation Excerpt :The effectiveness of this strategy on other diseases led to the search for therapeutic targets in patients with Systemic Lupus Erythematosus (SLE) in the last few years [2]. The 2014 recommendations on the treat-to-target strategy in SLE suggested that the therapeutic targets should be remission and, when this is not possible, the lowest possible level of disease activity, since SLE disease activity is associated with adverse patient outcomes, including damage accrual and mortality [1,4–9]. Thus, there was a need to define low disease activity (LDA) and remission, not only for their use in clinical practice but also as outcomes in randomized controlled trials (RCT) [3].
Involvement of N6-methyladenosine modifications of long noncoding RNAs in systemic lupus erythematosus
2022, Molecular ImmunologySystemic lupus erythematosus (II). Therapeutic strategy
2021, Medicine (Spain)